Sunday, May 27, 2018

Northrim BanCorp (NRIM) versus Hometrust Bancshares (HTBI) Financial Analysis

Northrim BanCorp (NASDAQ: NRIM) and Hometrust Bancshares (NASDAQ:HTBI) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

Get Northrim BanCorp alerts:

This is a summary of current recommendations and price targets for Northrim BanCorp and Hometrust Bancshares, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Northrim BanCorp 0 0 0 0 N/A
Hometrust Bancshares 0 2 0 0 2.00

Hometrust Bancshares has a consensus price target of $27.50, suggesting a potential upside of 2.04%. Given Hometrust Bancshares’ higher possible upside, analysts plainly believe Hometrust Bancshares is more favorable than Northrim BanCorp.

Earnings and Valuation

This table compares Northrim BanCorp and Hometrust Bancshares’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Northrim BanCorp $100.58 million 2.71 $13.15 million $2.04 19.46
Hometrust Bancshares $114.88 million 4.47 $11.72 million $0.94 28.67

Northrim BanCorp has higher earnings, but lower revenue than Hometrust Bancshares. Northrim BanCorp is trading at a lower price-to-earnings ratio than Hometrust Bancshares, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Northrim BanCorp and Hometrust Bancshares’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Northrim BanCorp 13.47% 8.45% 1.08%
Hometrust Bancshares 4.40% 5.97% 0.74%

Volatility & Risk

Northrim BanCorp has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Hometrust Bancshares has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.

Dividends

Northrim BanCorp pays an annual dividend of $0.96 per share and has a dividend yield of 2.4%. Hometrust Bancshares does not pay a dividend. Northrim BanCorp pays out 47.1% of its earnings in the form of a dividend.

Insider & Institutional Ownership

70.7% of Northrim BanCorp shares are held by institutional investors. Comparatively, 60.6% of Hometrust Bancshares shares are held by institutional investors. 2.9% of Northrim BanCorp shares are held by insiders. Comparatively, 6.3% of Hometrust Bancshares shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Northrim BanCorp beats Hometrust Bancshares on 8 of the 14 factors compared between the two stocks.

About Northrim BanCorp

Northrim BanCorp, Inc. operates as the bank holding company for Northrim Bank that provides commercial banking products and services to businesses and professionals in Alaska. The company operates in two segments, Community Banking and Home Mortgage Lending. It offers various deposit products, including noninterest-bearing checking accounts and interest-bearing time deposits, checking accounts, and savings accounts, as well as money market deposit accounts, certificates of deposit, and courier noncash deposits. The company also provides family residential mortgages; commercial loans, such as secured and unsecured loans for working capital and expansion; commercial real estate loans; construction loans for commercial real estate projects, and land development and residential subdivision construction loans; and consumer loans comprising loans for automobiles, recreational vehicles, boats, and other consumer purchases, as well as home equity and commercial credit lines, and factoring services. In addition, it offers other services comprising consumer online banking, mobile app and mobile deposit, mobile Web and text banking, business online banking, personal finance, online documents, consumer and business debit cards, personalized checks at account opening, telebanking, automated teller, overdraft protection from a savings account, commercial drive-up banking, automatic transfers and payments, wire transfers, direct payroll deposit, electronic tax payments, automated clearing house origination and receipt, remote deposit capture, merchant, and cash management services, as well as annuity products, and long term investment portfolios. As of January 29, 2018, the company operated 14 branches in Anchorage, the Matanuska Valley, Juneau, Fairbanks, Ketchikan, and Sitka. Northrim BanCorp, Inc. was founded in 1990 and is headquartered in Anchorage, Alaska.

About Hometrust Bancshares

HomeTrust Bancshares, Inc. operates as the bank holding company for HomeTrust Bank that provides a range of retail and commercial banking products. Its deposit products consist of savings, money market, and demand accounts, as well as certificates of deposit for individuals, businesses, and nonprofit organizations. The company's loan portfolio comprises retail consumer loans, such as one-to-four-family residential property lending, home equity lines of credit, construction and land/lots, indirect auto finance, and consumer lending; and commercial loans, including commercial real estate lending, construction and development lending, and commercial and industrial loans. It also provides ground and equipment lease financing to fire departments. As of June 30, 2017, the company operated 42 offices in North Carolina, Upstate South Carolina, East Tennessee, and Southwest Virginia. HomeTrust Bancshares, Inc. was founded in 1926 and is headquartered in Asheville, North Carolina.

Saturday, May 26, 2018

This Rare-Disease Biotech Scores an Important Win

After the FDA approved Palynziq (formerly pegvaliase) for use in adults with phenylketonuria (PKU), a rare genetic disease, this week,�BioMarin Pharmaceutical�(NASDAQ:BMRN)�is in a great position to add hundreds of millions of dollars in new revenue to its top line. BioMarin already markets one PKU therapy, Kuvan, so it should be able to hit the ground running. Is BioMarin a stock worth buying now?

What is PKU?

A genetic disease caused by an inability to break down an amino acid, PKU can result in the toxic buildup of phenylalanine in the brain, particularly if patients consume�protein-rich foods or foods containing aspartame, an artificial sweetener.

A person holds a rubber stamp in his hand with the word approved printed on it.

IMAGE SOURCE: GETTY IMAGES.

As phenyalanine levels increase to dangerous levels, it can cause irreversible brain damage, developmental delays, and neurological problems, including seizure. It's a severe condition, but it's relatively rare. Globally, it impacts about 50,000 people.�

Because PKU is debilitating, all 50 states in the U.S. require PKU screening at birth. There's no cure for PKU, so treatment involves a lifelong dietary restriction that's very hard for patients to comply with. In�some PKU patients,�BioMarin's Kuvan, a pharmaceutical version of BH4, a natural substance that reduces phenyalanine levels by breaking it down, is also prescribed.

Currently, only about 12% of PKU patients, most of whom are children, take Kuvan, yet it's BioMarin's second best-selling product, with $408 million in sales in 2017.

Reaching more PKU patients

Palynziq is a potent drug, and because of this, it's initially only being approved for use in adults with PKU. BioMarin believes roughly 12,000 adults in the U.S. could benefit from using its newly approved drug and that its worldwide addressable market totals about 33,000 people.�

An enzyme replacement approach, Palynziq substitutes the deficient phenylalanine enzyme in PKU with a version of the enzyme phenylalanine ammonia lyase, which can break down�phenyalanine.�

Immune responses, including anaphylaxis, occurred in Palynziq's trials, so the FDA approval includes a REMS program, and the dosing of it in patients will be titrated over four to six months to improve tolerability and so that patients can take the lowest effective dose. In trials, 11% of patients discontinued Palynziq because of adverse reactions.�

While safety concerns can't be ignored, Palynziq is a first-of-its-kind solution for adult patients, and its efficacy could allow BioMarin to treat substantially more PKU patients than Kuvan. According to BioMarin's management, Palynziq has billion-dollar per year peak sales potential.

Initially, BioMarin's focus will be converting the 200 adult PKU patients that participated in Palynziq's trials into commercial users. Once that's done, the company will focus on the 2,300 adult Americans who are being treated in clinics, and then, it will embrace a strategy to reach the roughly 7,500 patients who are diagnosed with PKU, but who haven't sought out treatment at a clinic for at least two years.

BioMarin expects that Palynziq will be available commercially in late June at an average expected cost of $192,000 per patient per year. At that price, the company would generate $38.4 million in annual sales if it converts the 200 trial participants into regular patients and $480 million per year if it also successfully gets Palynziq prescribed to the 2,300 people being treated in clinics.�

Pricing isn't likely to be as high outside of the U.S., but the addressable market there is bigger, so an EU approval would also be meaningful.�EU regulators accepted Palynziq's application for approval earlier this year, and overall, management says there are 15,000 adult PKU patients in Europe and Turkey, including 4,900 who are being treated in clinics.

What's on deck

Kuvan's use in children should continue to make it a top-seller for the company, at least until generics become available. BioMarin has licensed rights to two generic drugmakers, and generic Kuvan could arrive�as soon as October 2020.

In the meantime, BioMarin will enjoy a dominant position in PKU that will help BioMarin take another step toward achieving profitability. Following Palynziq's OK, BioMarin has now won approvals for seven drugs. In 2017, the company's global revenue was $1.3 billion, so the potential to add hundreds of millions of dollars in new sales would significantly move the needle.�

BMRN Revenue (Annual) Chart

BMRN Revenue (Annual) data by YCharts.

In addition to improving progress toward profit, the additional revenue will also come in handy in support of BioMarin's R&D pipeline, including a potentially game-changing PKU gene therapy.�BioMarin hopes to begin human trials for a gene therapy that could restore the production of the missing enzyme in PKU patients in 2019.�The potential for a one-and-done gene therapy in PKU would significantly disrupt the market.

Overall, the impact Palynziq may have on BioMarin's financials in the next year or two, and the opportunity longer-term to create even better treatments for PKU, make it an interesting stock that I think is worth buying in growth portfolios.

Friday, May 25, 2018

This Day In Market History: NYSE Starts Disclosing Short Sales

Each day, Benzinga takes a look back at a notable market-related moment that occurred on this date.

What Happened?

On this day 87 years ago, the New York Stock Exchange began regularly reporting short selling data for the first time.

Where The Market Was

The Dow finished the day at 132.87. The S&P 500 traded at around 13.80. Today, the Dow is trading at 24,811.76 and the S&P 500 is trading at 2,727.76.

What Else Was Going On In The World?

In 1931, the Empire State Building opened its doors in New York, and unemployment in the U.S. doubled to 16.3 percent as the Great Depression set in. A loaf of bread cost 8 cents.

Short Sellers Come Out Of The Shadows

The Dow dropped 32.6 percent in 1930 as the American economy took a nosedive, but short sellers in the stock market made a killing. Short sellers took a lot of heat for the stock market crash of 1929, which led to the enactment of the uptick rule shortly thereafter. The uptick rule requires short selling orders to be filled only during upticks in share prices and is meant to mitigate the negative impact of short sales. The uptick rule was abolished in 2007 just prior to the market crash of 2008.

In May 1931, the NYSE made the decision to regularly disclose short sale data for the first time so traders could know just how much money was being bet against the market.

Today, traders routinely use short-selling-related metrics such as short volume, short interest, utilization rate and short percent of float to help inform trading decisions.

Related Links:

This Day In Market History: AOL Is Founded

Inogen Hit By Citron Report; Analyst Rebuttal Calls This 'An Excellent Entry Point'

Photo by Thomas J. O'Halloran via the Library of Congress. 

Tuesday, May 22, 2018

Best China Stocks To Buy For 2018

tags:ENV,NWL,MGK,CCU,RBCN,STNG,

The U.S. has a new bargaining chip on the table when it comes to Iranian sanctions: Shale.

In 2012, American oil stayed on American shores, giving the U.S. less leverage to compel powerhouse oil-consuming countries like India and China to sanction Iran. That was then, this is now. The crude export ban is lifted, and “the U.S. is as large of an exporter as Iran -- 2.5 million barrels a day,” Jeff Currie, Goldman Sachs Group Inc’s global head of commodities, said Thursday in an interview with Bloomberg TV.

“That now gives them a bargaining chip -- saying -- ‘Hey, if you don’t comply, we can take away those barrels,’” he said. “It is a way to enforce compliance on refiners around the world.”

Sanctions on Iran will reduce the Islamic Republic’s ability to produce and export, but the lost oil supply will be supplanted by allies of the U.S., like Saudi Arabia, Currie said. While there is “a lot of geopolitical stuff going on,” the current oil rally is underpinned by real demand, not the headlines, he said.

Best China Stocks To Buy For 2018: Envestnet, Inc(ENV)

Advisors' Opinion:
  • [By Dan Caplinger]

    Financial services companies rely on the health of the markets to bring them business from the large institutions that are their best customers. With a bull market that's almost a decade long at this point, Wall Street has never been stronger, and that's given a big boost to financial information technology specialist Envestnet (NYSE:ENV). Yet as volatility returns to the stock market in early 2018, some investors feared that Envestnet's time in the sun might soon end and give way to more difficult conditions looking ahead.

  • [By Stephan Byrd]

    Zillow (NASDAQ: ZG) and Envestnet (NYSE:ENV) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Best China Stocks To Buy For 2018: Newell Rubbermaid Inc.(NWL)

Advisors' Opinion:
  • [By ]

    Starboard Value's Jeff Smith on Wednesday officially launched a boardroom battle at Newell Brands Inc. (NWL) , offering up a minority-slate of four candidates that will partly go up against directors recently installed by rival billionaire insurgent Carl Icahn, in a skirmish over which activist fund will be better able to oversee $10 billion worth of asset sales at the Mr. Coffee maker.

  • [By ]

    Not every battle is worth fighting, Cramer told viewers. That's especially true if you own shares of Newell Brands (NWL) , which is embroiled in a bitter proxy fight between activists Starboard Capital and Carl Icahn.

  • [By ]

    Not every battle is worth fighting, Cramer told viewers. That's especially true if you own shares of Newell Brands (NWL) , which is embroiled in a bitter proxy fight between activists Starboard Capital and Carl Icahn.

  • [By Lisa Levin] Gainers Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) rose 34.7 percent to $45.50 in pre-market trading following news that the FDA has approved Andexxa for the reversal of factor Xa inhibitors. Euro Tech Holdings Company Limited (NASDAQ: CLWT) rose 15.7 percent to $6.65 in pre-market trading after climbing 155.56 percent on Thursday. China Recycling Energy Corporation (NASDAQ: CREG) rose 14.7 percent to $2.75 in pre-market trading after climbing 57.89 percent on Thursday. Pandora Media, Inc. (NYSE: P) rose 11 percent to $6.40 in pre-market trading after reporting strong quarterly results. Fred's, Inc. (NASDAQ: FRED) rose 9.2 percent to $1.90 in pre-market trading following Q4 results. Shake Shack Inc (NYSE: SHAK) rose 9.1 percent to $51.70 in pre-market trading after the company reported upbeat results for its first quarter and raised its FY18 guidance. Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) rose 9 percent to $12.55 in pre-market trading after the company posted Q1 results and agreed to acquire HealthGrid. Weight Watchers International, Inc. (NYSE: WTW) rose 7.6 percent to $75 in pre-market trading after the company reported stronger-than-expected results for its first quarter. The company also raised its FY18 earnings outlook from $2.40-$2.70 to $3-$3.20. Viavi Solutions Inc. (NASDAQ: VIAV) rose 7.5 percent to $10.15 in pre-market trading following Q3 results. Pearson plc (NYSE: PSO) rose 4.5 percent to $11.83 in pre-market trading after reporting strong quarterly earnings. Alibaba Group Holding Ltd (NYSE: BABA) shares rose 4.4 percent to $190.50 in the pre-market trading session as the company posted upbeat Q4 results. Aqua Metals, Inc. (NASDAQ: AQMS) shares rose 3.9 percent to $4.30 in pre-market trading after gaining 6.98 percent on Thursday. Newell Brands Inc (NYSE: NWL) shares rose 3.6 percent to $27.65 in pre-market trading after reporting upbeat quarterly earnings. HMS Holdings Corp (NASDAQ: H

Best China Stocks To Buy For 2018: Vanguard Mega Cap Growth ETF (MGK)

Advisors' Opinion:
  • [By Ethan Ryder]

    Fernwood Investment Management LLC lessened its stake in VANGUARD MEGA CAP 300 GROWTH ETF (BMV:MGK) by 9.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,022 shares of the company’s stock after selling 1,698 shares during the period. VANGUARD MEGA CAP 300 GROWTH ETF comprises 1.1% of Fernwood Investment Management LLC’s portfolio, making the stock its 26th biggest holding. Fernwood Investment Management LLC owned approximately 0.06% of VANGUARD MEGA CAP 300 GROWTH ETF worth $1,911,000 as of its most recent filing with the SEC.

Best China Stocks To Buy For 2018: Compania Cervecerias Unidas, S.A.(CCU)

Advisors' Opinion:
  • [By Dan Caplinger]

    Beverage stocks have been a hit-or-miss proposition in the U.S., both for megabrewers and for smaller players in the craft beer, spirits, and soft drink industries. But there are plenty of opportunities internationally to invest in the companies that produce drinks. In Chile, Compania Cervecerias Unidas (NYSE:CCU) produces beer, wine, and soft drinks for several South American countries, and after having seen a slow period to finish 2017, CCU had hoped to find ways to bounce back to start the new year.

Best China Stocks To Buy For 2018: Rubicon Technology, Inc.(RBCN)

Advisors' Opinion:
  • [By Logan Wallace]

    Rubicon Technology (NASDAQ:RBCN) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Thursday.

Best China Stocks To Buy For 2018: Scorpio Tankers Inc.(STNG)

Advisors' Opinion:
  • [By Max Byerly]

    Get a free copy of the Zacks research report on Scorpio Tankers (STNG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Rich Smith]

    Stocks don't always make sense -- a fact�investors should be happy about after�Scorpio Tankers (NYSE:STNG) posted a quarterly loss and an earnings miss this morning and then rocketed 15% in early trading.

  • [By Lisa Levin]

    Wednesday afternoon, the energy shares gained 0.74 percent. Meanwhile, top gainers in the sector included Pengrowth Energy Corporation (NYSE: PGH), up 12 percent, and Scorpio Tankers Inc. (NYSE: STNG), up 12 percent.

  • [By Lisa Levin] Gainers Daré Bioscience, Inc. (NASDAQ: DARE) shares jumped 56.69 percent to close at $1.27 on Wednesday on news that the company entered into worldwide license agreement for Juniper Pharmaceuticals' intravaginal ring technology platform. Vicor Corporation (NASDAQ: VICR) rose 26.84 percent to close at $37.10. Vicor posted Q1 earnings of $0.10 per share on sales of $65.2 million. AGM Group Holdings Inc. (NASDAQ: AGMH) climbed 25.56 percent to close at $10.61. Travelzoo (NASDAQ: TZOO) gained 24.7 percent to close at $9.75 following strong Q1 results. Intrepid Potash, Inc. (NYSE: IPI) shares climbed 19.24 percent to close at $4.71. China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 18.73 percent to close at $18.64. Genprex, Inc. (NASDAQ: GNPX) climbed 18.28 percent to close at $5.89. Genprex expanded its operations to Cambridge, Mass. Scorpio Tankers Inc. (NYSE: STNG) rose 13.92 percent to close at $2.70 following Q1 results. Rocky Brands, Inc. (NASDAQ: RCKY) shares surged 13.57 percent to close at $23.85 after reporting Q1 results. Resonant Inc. (NASDAQ: RESN) shares rose 12.5 percent to close at $4.14 on Wednesday. USANA Health Sciences, Inc. (NYSE: USNA) jumped 11.24 percent to close at $106.85 following Q1 results. SUPERVALU Inc. (NYSE: SVU) rose 11.16 percent to close at $16.24 after the company reported Q4 results and agreed to sell and leaseback eight distribution centers for an aggregate purchase price of $483 million. K12 Inc. (NYSE: LRN) shares gained 10.74 percent to close at $15.36 following Q3 results. Tupperware Brands Corporation (NYSE: TUP) rose 9.15 percent to close at $46.28 as the company posted in-line quarterly earnings. Six Flags Entertainment Corporation (NYSE: SIX) shares climbed 8.49 percent to close at $64.18 as the company posted a narrower-than-expected loss for its first quarter. Carlisle Companies Incorporated (NYSE: CSL) gained 8.2 percent to close at $107.94 af

Monday, May 21, 2018

Buy Strides Shasun; target of Rs 980: HDFC Securities


HDFC Securities' research report on Strides Shasun


After� the� proposed merger of Apotex��s Australia business, with almost 50% market� share, STR will become the largest generic player in the region. It will� also� gain the priority access to 58% of Australian pharmacies.� Till now,� three� large� generic� players� have controlled more than 78% generic market and pharmacy reach had become the major barrier for any new entrant.

Outlook

With� improving� traction� in� both� Australia and US geographies and fresh institutional� orders� for Anti-malarial products, we believe the operating performance� of� the� overall� business is likely to show sharp improvement over� next few quarters. Maintain BUY rating with a TP of Rs 980 (16x FY20E + Rs 30/sh for biopharma).

For all recommendations report,�click here


Disclaimer:�The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More

Sunday, May 20, 2018

EAGLE POINT CREDIT COMPANY (ECC) Q1 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

Image source: The Motley Fool.

EAGLE POINT CREDIT COMPANY�(NYSE:ECC) Q1 2018 Earnings Conference CallMay. 17, 2018 10:00 a.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Good morning. My name is Virgil, and I will be your conference operator today. At this time, I would like to welcome everyone to the Eagle Point Credit Company first-quarter 2018 earnings conference call. All lines have been placed on mute to prevent any background noise.

After the speakers' remarks, there will be a question-and-answer session [Operator instructions]. Thank you.Garrett Edson, senior vice president, ICR, you may begin your conference.

Garrett Edson -- ICR Investor Relations

Thank you, Virgil, and good morning. By now, everyone should have access to our earnings announcement and investor presentation, which was released prior to this call, which may also be found on our website at eaglepointcreditcompany.com. Before we begin our formal remarks, we need to remind everyone that the matters discussed on this call include forward-looking statements or projected financial information that involve risks and uncertainties that may cause the company's actual results to differ materially from those projected in such forward-looking statements and projected financial information.Further information on factors that could impact the company and the statements and projections contained herein, please refer to the company's filings with the Securities and Exchange Commission. Each forward-looking statement and projection of financial information made during this call is based on information available to us as of the date of this call.

We disclaim any obligation to update our forward-looking statements unless required by law. A replay of this call can be accessed for 30 days via the company's website eaglepointcreditcompany.com.Earlier today we filed our Form 10-Q first-quarter 2018 financial statements and first-quarter investor presentation with the Securities and Exchange Commission. Financial statements in our first-quarter investor presentation are also available on the company's website. Financial statements can be found by following the financial statements and reports quick link on our website.

The investor presentation can be found by following the investor presentation and portfolio information quick link on our website.I would now like to introduce Tom Majewski, chief executive officer of Eagle Point Credit Company.

Thomas P. Majewski -- Chief Executive Officer

Thank you, Garret, and welcome, everyone to Eagle Point Credit Company's first-quarter Earnings Call. If you haven't done so already, we invite you to download our supplemental investor presentation from our website, which provides additional information regarding our portfolio and the underlying corporate loan obligors. As we've done previously, I'll provide some high-level commentary on the quarter then I'll turn the call over to Ken who will walk us through the first-quarter financials in a little more detail. I'll then return to talk about the macro environment, our strategy and provide some updates on recent activity.

And of course, we'll open the call to questions at the end.The first quarter really picked up right where we left off in 2017 as we continue to actively deploy capital into new investments. We opportunistically harvested gains and completed resets of a number of CLOs in our portfolio. During the quarter, we deployed approximately $91.6 million in gross capital into new investment. The new CLO equity repurchase had a significantly higher weighted average effective yield than the weighted average for our overall portfolio.

That overall weighted average of our CLO equity portfolio also increased quarter over quarter.Additionally, where we saw an opportunity and appropriate pricing, we sold certain CLO equity and debt investments, and we locked in about $1.8 million of realized gains during the quarter. We also leveraged our advisors' competitive strength and a broader portfolio and closed on four resets during the first quarter.Beyond our portfolio activity, which makes up I guess the left side of our balance sheet, we've also sought to create value for shareholders on the right side of the company's balance sheet. During the quarter, we completed a common stock offering at a premium to NAV, which has the effect of increasing NAV for all shareholders. In April, we closed on an offering of our new 11 -- or 6 and 11/16% 10-year ECC X notes.

These new X notes are over seven years longer than the Z notes they replace and were 31.25 basis points less expensive. In fact, the new notes represent the lowest cost of funds that the company has ever obtained. These savings will fall directly to ECC's bottom line.We're utilizing proceeds from the ECC X offering to effectively refinance our 7% ECC Z notes next week, which will then extend the weighted average maturity of our preferred stock and unsecured notes outstanding to over eight years. Importantly, all of our financing is fixed-rate, which provides us with certainty and cost visibility, which is particularly important in a rising rate environment.

We're prudently capitalizing on the capabilities of our advisor and our overall platform to significantly improve the company's overall positioning.For the first quarter, we generated net investment income and realized gains of $0.50 per common share and that's a one penny increase from the prior quarter but it is still below our common distribution rate of $0.60 per quarter. During the first quarter, as I mentioned, we deployed approximately $91 million of capital on a gross basis in both the primary and secondary market. We made six primary CLO equity purchases, representing $35.9 million, nine strategic CLO debt purchases and made investments in six loan accumulation facilities. During the quarter, one of our loan accumulation facilities was converted into a CLO.The new CLO equity investments that went in the ground had a weighted average effective yield of 17.37% measured at the time of investment.

And once again, that's well above the overall weighted average of our CLO equity portfolio, which as of March 31 was 14.54%. This continues to demonstrate our ability to source accretive investments in a strong credit market through our advisors' investment process.On the monetization side, we sold $24.8 million of CLO equity, as well as $9.5 million of CLO debt securities. Together, these sales allowed us to realize $1.8 million of net gains versus amortized cost. While we typically underwrite investments with a long-term hold mindset, we do sell investments when our advisor believes the price available is better than what our outlook for the investment warrant.

Looking back, we're pleased that we've had realized gains in seven of the last eight quarters.

We discussed on our last call, the capabilities and deep experience of our advisor, which proactively gets involved throughout the investment process and lifecycle to try and create additional value throughout the lives of our investments. Our advisors' active management of the end of an investment life is just as important as investment selection at the outset. As our portfolio continues to season, our advisor expects us to become increasingly active with respect to reset.Our existing portfolio, comprising positions in dozens of CLOs where ECC and other clients of our advisor collectively own the majority of the CLOs equity class, as well as the evergreen structure of the company, provides us with a meaningful advantage in pursuing additional value for CLO reset. We believe there are few other investors with as many majority positions as our advisor.In the first quarter, we priced four resets, bringing the total number of the resets that the company has been involved in from January 2017 through the first quarter of this year to 10.

The reset completed in the first quarter created new reinvestment periods of up to five years for those CLOs and reduced those CLOs' weighted average cost of debt. Importantly, our advisor has a robust pipeline of future resets under evaluation for the company's portfolio.As a reminder, a reset typically causes a one-time reduction in CLO equity cash flows as the cost associated with the reset is paid out of the CLOs' waterfall on the next payment date. However, while the near-term cash flow may be reduced, we believe this is money very well spent and that our investments will harvest increased cash flows to our CLO equity securities in the future, had we not taken these actions. Of course, wherever possible, our advisor seeks to keep those service provider costs to a minimum.As of March 31, the weighted average effective yield on our CLO equity portfolio was 14.54%.

That's up from 14.42% in the prior quarter but down from 16.2% as of March 31, 2017. A modest increase suggests that we may have reached an inflection point after a year of declining yield due to the marketwide reduction in loan spreads, aided by our recent investments, as well as our proactive refi and reset activity. As I've noted previously and shared with you multiple times, the weighted average effective yield that we use includes an allowance for future credit losses. A summary of investment-by-investment changes in expected deals are included in our quarterly investor presentation as well.On the capital front, in addition to our underwritten common stock offering and the ECC X notes that I mentioned earlier, we utilized our at-the-market program during the quarter to issue approximately 296,000 common shares, all at a premium to NAV.

Ken will provide more particulars but since we began the program last summer running through the first quarter of this year, we've received net proceeds from the sale of new common stock of about $16.5 million.In April and in the beginning of May, we've deployed a net $15.8 million of capital across CLO equity and debt investments, as well as loan accumulation facilities. Through May 11, in the second quarter, one additional CLO has been reset. In addition to resetting existing investments, we continue to actively pursue new primary investments, which we expect to price into CLOs and that we expect to benefit from some of the lowest financing spreads we've achieved on any investments in our portfolio. Our team continues to work hard to find attractive opportunities.

And we believe the company is well-positioned to capitalize on them.Overall, our long-term outlook for our portfolio remains quite favorable. We believe the recent investments continue to position the company very well. As you've seen over the past couple quarters, we continue to purchase CLO equity securities where weighted average effective yields are meaningfully above the overall CLO portfolio effective yield. Many of our newly created CLOs benefit from some of the lowest debt spreads than any of our CLOs.

We're very happy with what's going in the ground today.After Ken's marks, I'll take you through the current state of the corporate loan and CLO markets, as well as our outlook for the remainder of 2018. I'll now turn the call over to Ken.

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

Thanks, Tom. Let's go through the first quarter in a bit more detail. For the first quarter of 2018, the company reported net investment income and realized capital gains of approximately $10.3 million in the aggregate, or $0.50 per common share. This was comprised of the net investment income of $0.41 per common share and net realized capital gains of $0.09 per common share.

This compares to net investment income and net realized capital gain of $0.49 per common share in the previous quarter and $0.60 per common share in the first quarter of 2017.When unrealized portfolio depreciation is included, the company recorded GAAP net income of approximately $8.1 million, or $0.39 per common share for the first quarter of 2018. This compares to net income of $0.68 per common share in the previous quarter and $0.05 per common share in the first quarter of 2017.The company's first-quarter net income was comprised of total investment income of $70 million and net realized capital gains of $1.8 million, which were partially offset by total expenses of $8.5 million and net unrealized depreciation or mark-to-market losses of $2.2 million. At the beginning of the first quarter, the company held $1.4 million of cash, net of pending investments. As of March 31, that amount was $8.3 million, reflecting our common equity capital raise and a number of opportunistic sales during the quarter.

As a result of deploying $41.1 million in net capital during the first quarter, there was a significant amount of capital that only generated income for a portion of the quarter, which we expect to generate full income going forward.As of March 31, the company's net asset value was approximately $355 million, or $16.65 per common share. Each month, we publish on our website an unaudited managing estimate of the company's monthly NAV, as well as quarterly NII and realized capital gains or losses. Management's unaudited estimate of the range of the company's NAV as of April 30 was between $16.71 and $16.81 per common share. Based on the range of midpoint, this is an increase of approximately 0.7% since prior month.

Net GAAP return on common equity in the first quarter was 2.55%.The company's asset coverage ratios at March 31st for preferred stock and debt as calculated pursuant to investment company act requirements were 290% and 581% respectively. These measures are above the statutory minimum coverage requirements of 200% and 300% respectively. As of March 31, the company had debt and preferred securities outstanding totaling approximately 35% of the company's total assets less current liabilities, below the 37% noted in the prior quarter. These previously communicated management expectations under current market conditions of generally operating the company with leverage in the form of debt and/or preferred stock within a range of 25% to 35% of total assets.Moving on to our portfolio activity in the second quarter through May 11.

Investments that have reached their first payment date are generating cash flows in line with our expectations. In the second quarter of 2018 as of May 11, the company received total cash flows on its investment portfolio, including the proceeds from called investments, totaling $28.8 million, or $1.35 per common share. This compares to $22.7 million of total cash flow received during the full first quarter of 2018. Consistent with prior quarter, we want to highlight that some of our investments are expected to make payments later in the quarter.During the first quarter, we paid three distributions of $0.20 per share of common stock as scheduled and on April 2, to peg monthly distributions of $0.20 per share of common stock for each of April, May, and June.

We completed an underwritten public offering in the first quarter of over 2.2 million shares of common stock, including the full exercise of the greenshoe at an offering price of $18.25 per share.The company received total net proceeds of approximately $38.8 million. Pursuant to our at-the-market offering program for common stock and 7.75% Series B preferred stock, during the first quarter, the company sold approximately 296,000 shares of its common stock at a premium to NAV for total net proceeds for the company of approximately $5.2 million.As Tom previously mentioned, subsequent to quarter-end, the company announced a closed and underwritten public offering of 6.6875% unsecured notes due 2028 resulting in net proceeds to the company of approximately $65 million inclusive of the partial exercise of the greenshoe. The company also announced it will redeem 100% or $60 million aggregate principal amount of its 7% 2020, ECC Z notes on May 24, effectively conducting a refinancing by using the vast majority of the ECC X proceeds with fully reading the EEC Z notes. This will result in lowering the company's ongoing interest costs, while also extending its debt maturities.In the second quarter, the company will be required to take a charge of $1.6 million related to ECC Z's unamortized issuance costs as a result of the full redemption.

For period subsequent to the quarter ending March 31, 2018, the company is changing its accounting policy related to newly issued debt securities and preferred stock by electing to recognize debt issuance costs in the period in which such costs are incurred. In prior periods when issuing debt securities are preferred stock, the company amortized such expenses over the stated maturity of the security. Beginning in the second quarter of 2018, the company will now take a one-time upfront charge of such expenses. Issuance costs related to ECC A, B, and Y will continue to be accounted for under the old policy.For the quarter ending June 30, 2018, management estimates one-time non-recurring costs related to the issuance of ECC X notes and the acceleration of the unamortized issuance costs associated with the redemption of the Z notes will impact NII and realized gains and losses for the quarter by approximately $0.20 per common share.

Unlike last year, we do not expect the need to pay a special distribution for the tax year ending November 30, 2017, as taxable income came in slightly below the company's common distributions for the same period.However, we would like to point out a meaningful diver of lower taxable income was a result of the significant amount of refinancings and resets, the company directed and/or participated in during 2017, which allows for the accelerated expense recognition of previously unamortized debt issuance costs and original issue discount within the CLO structures.I would now like to hand the call back over to Tom to discuss the current status of our portfolio and the overall market.

Thomas P. Majewski -- Chief Executive Officer

Great. Thank you very much, Kim. Let me first take the call participants through some macro loan and CLO market observations, and we could talk about how they may impact the company. And then I'll touch a little further on some of our recent portfolio activity.

Through April 24, the Credit Suisse Leverage Loan Index generated a total return of 2.05%, generally in line with where that index was at that time last year. And according to J.P. Morgan and their index, over 70% of loans in their index are trading par.During the first quarter, we saw loan fund flows reverse course from the end of 2017 with open-end loan mutual funds observing about $2.9 billion in retail inflows according to data from J.P. Morgan.

While a significant amount of loans continue to trade above par, we believe that the muted amount of fund inflows is still acting as a bit of a headwind for further loan refinancing or repricing activity. Indeed, during the first quarter of 2018, we saw a fair bit left amount of loan repricing than we did in the first quarter of 2017. It's still happening just at a slower rate, which is good for us we believe.The total amount of institutional corporate loans outstanding was $994 billion as of March 31, a 12% increase from the prior year and 4% up from the end of 2017, according to S&P Capital IQ. Institutional new loan volume was about $130 billion in the first quarter, keeping pace with last year's record performance and driven significantly still by refinancing, which made up a big part of the activity.

The institutional corporate loan market is large and provides a broad investible market for our CLOs to invest and reinvest in.In terms of corporate defaults for large-cap loan default rates remain quite low with a lagging 12-month default rate of only 2.4% at the end of March, according to S&P Capital IQ. And we and others certainly expect rates to remain around these levels due to minimal and pending maturities, certainly in an economy that's gaining in robustness and the large majority of the loan market consisting of covenant like loans. The Company's overall credit expense remained below long-term averages. Should volatility and price dislocations occur, we believe the company and its investments will be well-positioned to take advantage of those opportunities.In the CLO market through April 24, we've seen about $39 billion of new CLO issuance along with about $37 billion of resets, and $9 billion of refinancing, putting the new issue and resets on pace to match or beat last year's records according to information from Deutsche Bank.

For the full year of 2018, our advisor continues to estimate between $90 billion and $110 billion of new issue volume, about $70 billion of resets and approximately $30 billion of refinancing.With the expectations for interest rates to be consistently rising in 2018 and '19, floating-rate CLO debt interest remains strong with new issue AAAs often pricing a little over 100 basis points for some of the most well-known collateral managers. BBs further down in the capital structure, which softened in March and April, now appear more keenly did as well. So far this quarter, we've reset one CLO and we've also deployed net capital of $15.8 million across CLO equity debt and loan accumulation facilities so far in the quarter, putting that undeployed capital to use as opportunistically as possible. Beyond seeking to maximize the value of our investments, we continue to maintain good visibility on our new investment pipeline for the next few quarters.To sum up, the start of the year was a very positive one for the company.

We deployed over $90 million of new capital into new investments. We've reset five CLOs so far this year and have a robust pipeline of resets under evaluation or negotiation. The weighted average affected yield on our CLO equity portfolio increased versus the prior quarter. We issued stock via an offering and through the ATM, both at premiums to NAV, helping to build NAV for all shareholders.And we issued unsecured debt with the lowest cost of capital that Company has ever achieved.

And through the refinancing of the Zs, or repayment of them, we significantly lengthened the company's debt and preferred stock maturity profile. We're very proud of all those accomplishments and we'll continue to be very proactive in our management of the company in order to create long-term value for our stockholders.We thank you for your time and interest in Eagle Point. Ken and I will now open the call to questions.

Questions and Answers:

Operator

[Operator instructions]. Your first question comes from Alison [Inaudible] from Oppenheimer. Please go ahead.

Alison -- Oppenheimer & Company -- Analyst

So you guys have expressed confidence in the past that net investment income plus realized gains should be able to shake your distribution level. And I'm curious about some of the specific drivers that we could look at to gauge progress on that front in the current environment. Perhaps it's something you've done in the CLO liability management, perhaps on the asset side or some mix but I am curious about how you guys would attribute the main drivers of that?

Thomas P. Majewski -- Chief Executive Officer

It's a couple of part answer. I'll try and keep it as distinct as possible. The credit expense part of the equation remains low. Though, we continue to reserve credit expense.

And we have dynamic of loan spreads compressing, although at a slower pace than it has been in the past. And our ability to put in new CLOs in the ground with lower cost debt and refinance and reset existing CLOs to get their debt cost down. Those are the different calculus of some of those. Obviously, loan spreads coming down are bad.

Our ability to refi, reset, and put new stuff on the ground to achieve embedded financing is good.The challenge we face is the pace of those are different and the granularity of those are different. And we have over 1,000 different corporate loans but I think I used this analogy in the past, fans coming out and golf ball size stuff that we're trying to tackle, because we have 50 or 60 different CLO securities or more that we're managing on the right side. What's played out is the net of all of those things, some favorable some unfavorable, is that we've seen the weighted average effective yield in the portfolio actually starts to tick up. This is the first quarter in more than I can recall unfortunately that we've had the weighted average yield move up on the overall portfolio and the paper we're putting in the ground today is certainly very accretive.

The common raise that we did in January does have a slight effect of distorting. So that added about a little over 2 million shares to the share count. A lot of that didn't start earning until later in the quarter as well, so that weighs things down. We look at it pro forma the earnings without the effect of those shares or the earnings and it certainly would have been higher.

The key part of our doing that raise, mindful we do have an ATM available to us, was to get the company back in line with the leverage target that we'd�set --�we had gone a touch�above it when we got the Ys�done back in August of last year. It was important to us to get a couple of that with the special last year. We wanted to get the ratio back in our targeted range but that certainly hurt earnings a few more cents.So, start looking at the yields flattened out, if anything, picking up a little bit. We're back on the side where we want to be within our own leverage guidelines, and we're putting good stuff in the ground.

And we've got a pretty strong pipeline of resets. One has already closed this quarter. Others have the price but not yet closed. And I can look at our trading floor right now and see people working on others as we speak.

So our part of optimizing the right side of the CLOs'�balance sheet I'd say is well under way.

Alison -- Oppenheimer & Company -- Analyst

And I guess one follow-up that I would have is just mechanically when you do, you said a CLO. Is there like a time horizon where you get a yield benefit perhaps in six to nine months as you work out the cost that you have to pay to do that or is that not necessarily how the yield model works?

Thomas P. Majewski -- Chief Executive Officer

For GAAP purposes, it is accretive as soon as it closes. So closing of a reset, we refresh the model, it's basically significantly a new model at that point and the yield from the old deal is disregarded and income has been accrued at that higher rate immediately. So, unfortunately, we've done a bunch, I think we've done 10 since the beginning of last year.We have a number of CLOs. If you look for our portfolio, that has non-call dates in the second quarter of this year, the third quarter of this year, which suggests those were 2016 vintage CLOs, which would, by virtue of that vintage, have some of the highest debt costs outstanding.

We have some with AAAs in the 150s and obviously are in a market where it's very low 100 today. Some of those are coming off of non-call. As we speak, we are working as keenly as possible to get those resets, which will be, we believe, some of the most potent resets that were ever done.

Operator

Your next question comes from Christopher Testa from National Securities. Please go ahead.

Christopher Testa -- National Securities -- Analyst

Just curious, Tom, could you talk about either par value or amortized cost of the total four resets during the quarter?

Thomas P. Majewski -- Chief Executive Officer

Yes, we're looking to find the numbers there, hang on.

Christopher Testa -- National Securities -- Analyst

No problem.

Thomas P. Majewski -- Chief Executive Officer

Let me just walk through the specific transactions. Before that closed, I don't have them but the total fair value as of March 31 of these was $25.777 million and the four transactions were CISE funding 2014, CISE 15-3, Octagon XVII, and CHL 14-2.

Christopher Testa -- National Securities -- Analyst

And could you quantify how much that impact to the portfolio cash distributions for the quarter, which was down pretty materially?

Thomas P. Majewski -- Chief Executive Officer

So, a couple of things on that. So, depending on the timing, some could have been Q1 payment changes, some could have been Q2 payment changes.

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

So two parts to that question, the four there that we spoke about in the first quarter that's going to generate $0.06 impact on cash flow in the subsequent quarter. For 2017 we're having $0.08 to $0.09 impact in the current quarter --

Christopher Testa -- National Securities -- Analyst

As you see the reset happens in December and affects the January payment, so the Q1 effective the April payment --

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

But there'll always be a quarter lag in the cash-flow recognition --

Christopher Testa -- National Securities -- Analyst

So there'll still be somewhat of a lag from the resets done in the first quarter for the current quarter now?

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

Yes, although the cash flows received to date are $28 million, we said versus $22 million in all of the first quarter. So despite what Ken said, which is a 100% accurate, cash flows are back up a whole bunch. And was down in the first quarter was three or four resets in fourth quarter of last year.

Christopher Testa -- National Securities -- Analyst

And I know Tom you have spoken about obviously the 2016 vintages which have some of the highest CLO debt costs are coming due when obviously probably, and I do see you guys to do more refinances. I am just wondering if you could give us a ballpark number of how much of your book has the non-call period expiring through the next couple of quarters?

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

They're with me, one second, we have that number. Just looking at the pipeline, I'd estimate $60 million plus of potential resets and refis during the second quarter.

Christopher Testa -- National Securities -- Analyst

Got it --

Thomas P. Majewski -- Chief Executive Officer

They're fixed on the fair value of that portfolio as of March 31, obviously, there's no assurance any of those transactions will happen. It's subject to the wins in the market but in current market conditions, we'd expect to be able to get a lot of those done. And if you look at in our portfolio summary page, you look at pages 4 and 5 of the investor presentation where we list the non-calls, you can see a fair number of 2018 non-call days and you can see they're generating non-trivial amounts of income. And if we are able to get a refinancing or reset off and lower the cost you would expect the income and cash to increase in future.Also if you look through pages 4 and 5, we added a column, Ken added this a couple of quarters ago, the refi reset call column.

And of the 50 investment or one through 50; once they're gone, they're not listed, but the vast majority of the portfolio of the first phase we've opened and maybe judgmentally here 30% to 40% of those listed on Page 5 but you can see the non-call days how we drive through things to get to them.

Christopher Testa -- National Securities -- Analyst

Yes, that's definitely very helpful, thank you. And speaking, I guess more philosophically, on the refi and reset side. Assuming that you have let's say the ability to refinance $60 million at fair value during the current quarter. Is this an environment where you just want to get all the refinances done at once, or are you still looking to maybe stagger that in case spreads tighten even further and you're getting more favorable costs? Or are we still low on the liability cost side of things that you would say, well, why wait for an additional 5 bps of spread tightening, let's just take what we could get now?

Thomas P. Majewski -- Chief Executive Officer

Very good question, and one we debate a fair bit. The savings on the deals, particularly the 16 deals, it has the potential to be so radical. We've got deals with 150 and 160 AAAs, and we've even done 100 and 110 to pivot. And if it's 90 next week, we'll try then; but the stage A, it's so significantly opportunity cost to wait and find out is pretty high; but then B, we've also got a bunch more deals to do in the second half of the year as well, because if you look through that non-call page, you'll see we won't be bored in the summer or the fall once we get through the near-term batch, there's plenty more rolling off of non-call later in the year.

Most of our investment activity frankly, in 2016 occurred in the second half of the year. So we'd expect more things rolling off of non-call the second half and into January in 2019.

Christopher Testa -- National Securities -- Analyst

And you guys have been pretty active, especially in the current quarter with the purchases of CLO debt, which you call strategic. Tom, are these generally CLO debts where you're trading at a discount to par and you know that the deal is coming up on being called soon and you're making these opportunistic purchases or is there something else to that?

Thomas P. Majewski -- Chief Executive Officer

In nearly all cases, there're opportunistic purchases where they're at a discount, and we expect the bonds to total lag at par. In one or two cases, there may have been any of them. So, CIFC 15-3 was a reset that we did in the first quarter. ECC did end up buying a little bit of a single-B in that deal.

And as of the end of the quarter, we haven't sold, and I won't go any further from there but there was one where it made sense to take a little bit of debt, it was so cheap but with a goal of selling it again in the future, could be something that happened.So a few of them have been done in conjunction with the reset, and then some done in advance, you will see cut order 15-1. We actually bought a big block of flagship 8 single-Bs where ECC is the majority holder or that single-B on the flagship. So everything we put in the ground we put in the ground for a reason. We're not a CLO debt fund but sometimes that can be very attractive.

Christopher Testa -- National Securities -- Analyst

And the last one for me, if I may. Ken, you had alluded to that you guys are changing the accounting policy in terms of debt issuance costs. Just wondering what induced the change there?

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

So it's a one more reporting NII on a go-forward basis, probably tripping in about $0.05 to a penny per quarter on amortization of debt issuance cost. We think it's better to reflect and absorb these costs upfront and have a cleaner presentation, meaning no amortization of deferred debt issuance on a go-forward basis, we think that will be more applicable reporting.

Thomas P. Majewski -- Chief Executive Officer

As we thought about calling the Zs, we have a million and a half bucks or some number like that of unamortized cost.

Christopher Testa -- National Securities -- Analyst

Right --

Thomas P. Majewski -- Chief Executive Officer

Maybe absolute right decision but then as I got gees, now we got to take a charge now for a million and a half, let's just expense it, we're done and we're never going to have to -- well, except for the three securities where we still have unamortized issuance cost for anything new we put out, we'll make the right decision on that day and we won't have to worry about original cost.

Christopher Testa -- National Securities -- Analyst

OK, that makes sense. And just drilling down a little into the details on how this is going to be presented. I know that you're going to have basically, I guess, a realized loss on debt extinguishment of about $1.6 million but then the financing costs you had alluded to pertaining to the note issuance that you guys completed in the second quarter, that's going to be impacted, that's going to be above the NII line on your actual interest expense line.[Crosstalk]

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

So both of these items are going to be above the line as internally we expect --

Christopher Testa -- National Securities -- Analyst

OK --

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

Yes, the extinguishment of the Zs wouldn't qualify for the realized loss accounting --

Christopher Testa -- National Securities -- Analyst

Got it, OK --

Thomas P. Majewski -- Chief Executive Officer

But not extraordinary --

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

Yes, not extraordinary and the guidance term non-recurring for reporting at --

Christopher Testa -- National Securities -- Analyst

OK, got it. So it's going to be that realized loss, as well as the issuance cost above the NII line and you're expecting roughly $0.20 per share impact from those together?

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

That's correct.

Operator

Your next question comes from Douglas Crimmins from RVP. Please go ahead.

Douglas Crimmins -- Relative Value Partners -- Analyst

I got a question. Just help me think about how we should be thinking about you guys going forward with respect to secondary equity offerings. The last one kind of the wisp, as you guys was whispering a deal out there. The stock traded off around 7% or 8% and is trading comfortably above 19.5%.

And then there was about 5% plus of expenses. So the net, we're down about 13%. And then the net proceeds were a very small premium to NAV, so there was not particularly accretive, etc. And I mean is this the philosophy going forward, we've even seen some BDCs where the management company pays some portion of the fees but just help me understand how the other go forward equity issuance concept is going to work?

Thomas P. Majewski -- Chief Executive Officer

Very good question, and indeed there was some downward pressure on the stock price prior to issuance, don't know specifically what drove it but we acknowledge the price movement for sure. Overall, and the driver for that issuance, was to get our leverage ratio in line with management of 25 to 35. We had gone above it when the issued the Ys, and we were thrilled to get the Ys done, and we said it's worth an exception but the goal was to get back in line with that, and the total proceeds, which was in the mid-30s millions was enough, we sized it just to get with the shoe get back on size with that test.We do have the ATM. We shared we did about 290,000 shares in the first quarter.

That is a more elegant way to introduce capital into the company. Obviously, the exact direction anything goes, I suspect we'll see a mix of all of those over time. Although, as we've gotten more comfortable with how the stock behaves with the ATM, we may end up doing more on that side of the ledger and versus big bang offerings.

Douglas Crimmins -- Relative Value Partners -- Analyst

And what's expense load on the ATMs?

Thomas P. Majewski -- Chief Executive Officer

The cap is up to 2%, sometimes we were able to do at even less than that.

Douglas Crimmins -- Relative Value Partners -- Analyst

Yes, I mean we just saw --

Thomas P. Majewski -- Chief Executive Officer

We're bigger shareholders there, we get them --

Douglas Crimmins -- Relative Value Partners -- Analyst

I understand --

Thomas P. Majewski -- Chief Executive Officer

We get that price movement as well. The ATM is far more efficient, and it's more of just-in-time capital versus raising the hidden costs than it is raising $35 million or whatever now, deploy it versus a million coming in on a day when you need it, is a more elegant way to do it.

Operator

There are no further questions at this time. I will turn the call back over to the presenters.

Thomas P. Majewski -- Chief Executive Officer

Great, thank you very much again for dialing into the call today. We appreciate everyone's continued interest and support of Eagle Point Credit Company. To the extent folks have follow-up questions, please feel free to give Ken or me, or the team at ICR a call, we'd be happy to speak further. Thank you very much, and have a good day.

Operator

This concludes today's call, and you may now disconnect.

Duration: 45 minutes

Call Participants:

Garrett Edson -- ICR Investor Relations

Thomas P. Majewski -- Chief Executive Officer

Kenneth Onorio -- Chief Financial Officer and Chief Operating Officer

Alison -- Oppenheimer & Company -- Analyst

Christopher Testa -- National Securities -- Analyst

Douglas Crimmins -- Relative Value Partners -- Analyst

More ECC analysis

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

10 stocks we like better than Eagle Point Credit Company Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Eagle Point Credit Company Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of May 8, 2018

Saturday, May 19, 2018

Top 10 Penny Stocks To Watch For 2019

tags:SMSI,TIS,YRCW,SIRI,NICK,BDSI,CPHI,BDL,RMCF,UFPT,

With legal marijuana sales in North America expected to climb from $6.7 billion in 2016 to over $20 billion by 2020, the prices of some marijuana penny stocks will skyrocket right along with the 198% increase in sales.

Marijuana penny stocks are still speculative investments, and only some will see their share prices jump thanks to the industry's growth. But we want to make sure Money Morning readers are as informed as possible about what's going on in the pot penny stocks sector.

And we've found three marijuana companies whose share prices could rise as they buy out other cannabis companies. While we aren't recommending you buy these penny stocks, their acquisitions make them worth watching this September.

Top 10 Penny Stocks To Watch For 2019: Smith Micro Software Inc.(SMSI)

Advisors' Opinion:
  • [By Stephan Byrd]

    These are some of the news stories that may have impacted Accern’s scoring:

    Get Smith Micro Software alerts: Short Interest in Smith Micro Software (SMSI) Increases By 51.9% (americanbankingnews.com) Smith Micro Software’s (SMSI) CEO Bill Smith on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) Smith Micro Software (SMSI) Reports Q1 Loss of $0.10 (streetinsider.com) Smith Micro Reports First Quarter 2018 Financial Results (finance.yahoo.com) Smith Micro announces above market USD 7.0m private placement offering (financial-news.co.uk)

    Separately, ValuEngine upgraded shares of Smith Micro Software from a “sell” rating to a “hold” rating in a report on Friday, February 2nd.

Top 10 Penny Stocks To Watch For 2019: Orchids Paper Products Company(TIS)

Advisors' Opinion:
  • [By Lisa Levin] Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares rose 35.8 percent to $4.55. EVINE Live Inc. (NASDAQ: EVLV) gained 28.8 percent to $1.04. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ: AMZN) is exploring ways of marketing its products and services to consumers beyond the internet. Sanmina Corp (NASDAQ: SANM) shares surged 19.1 percent to $33.00 as the company reported stronger-than-expected earnings for its second quarter on Monday. Heidrick & Struggles International, Inc. (NASDAQ: HSII) gained 14.9 percent to $37.22 as the company posted upbeat results for its first quarter. Santander Consumer USA Holdings Inc. (NYSE: SC) shares climbed 14 percent to $17.90 following upbeat quarterly earnings. Helix Energy Solutions Group, Inc. (NYSE: HLX) climbed 14 percent to $7.12 following strong quarterly results. Check-Cap Ltd. (NASDAQ: CHEK) gained 13.6 percent to $8.25. Atossa Genetics Inc. (NASDAQ: ATOS) rose 11.8 percent to $3.34. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men. Cadence Design Systems, Inc. (NASDAQ: CDNS) gained 11.6 percent to $40.99 after the company posted upbeat Q1 results and issued a strong Q2 forecast. Genprex, Inc. (NASDAQ: GNPX) climbed 11.2 percent to $4.9363. Mitel Networks Corporation (NASDAQ: MITL) rose 10.5 percent to $11.23 after the company agreed to be acquired by affiliates of Searchlight Capital Partners for $2.0 billion. Systemax Inc. (NYSE: SYX) rose 10.2 percent to $30.86. Sidoti & Co. upgraded Systemax from Neutral to Buy. Orchids Paper Products Company (NYSE: TIS) surged 9.2 percent to $7.13. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018. New Oriental Education & Technology Group Inc. (NYSE: EDU) rose
  • [By Lisa Levin] Gainers Check-Cap Ltd. (NASDAQ: CHEK) shares jumped 104.82 percent to close at $14.87 on Tuesday. EVINE Live Inc. (NASDAQ: EVLV) rose 31.25 percent to close at $1.06. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ: AMZN) is exploring ways of marketing its products and services to consumers beyond the internet. SemiLEDs Corporation (NASDAQ: LEDS) shares climbed 27.16 percent to close at $4.26 on Tuesday. Atossa Genetics Inc. (NASDAQ: ATOS) gained 27.09 percent to close at $3.80. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men. Heidrick & Struggles International, Inc. (NASDAQ: HSII) surged 17.13 percent to close at $37.95 as the company posted upbeat results for its first quarter. Santander Consumer USA Holdings Inc. (NYSE: SC) shares gained 15.91 percent to close at $18.21 following upbeat quarterly earnings. Riot Blockchain, Inc. (NASDAQ: RIOT) shares jumped 15.73 percent to close at $7.58 on Tuesday after declining 1.50 percent on Monday. Sanmina Corp (NASDAQ: SANM) shares gained 14.62 percent to close at $31.75 as the company reported stronger-than-expected earnings for its second quarter on Monday. Orchids Paper Products Company (NYSE: TIS) jumped 12.86 percent to close at $7.37. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018. Helix Energy Solutions Group, Inc. (NYSE: HLX) rose 12.8 percent to close at $7.05 following strong quarterly results. Avid Bioservices, Inc. (NASDAQ: CDMO) rose 12.72 percent to close at $3.81. Genprex, Inc. (NASDAQ: GNPX) gained 12.61 percent to close at $5.00. Obalon Therapeutics, Inc. (NASDAQ: OBLN) rose 12.39 percent to close at $3.72. NextDecade Corporation (NASDAQ: NEXT) shares climbed 11.88 percent to close at $7

Top 10 Penny Stocks To Watch For 2019: YRC Worldwide Inc.(YRCW)

Advisors' Opinion:
  • [By Lisa Levin] Gainers Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 73.3 percent to $3.90. Integrated Media Technology Limited (NASDAQ: IMTE) shares gained 51 percent to $33.1365. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months. Monaker Group, Inc. (NASDAQ: MKGI) shares jumped 34 percent to $3.00. Sharing Economy International Inc. (NASDAQ: SEII) shares rose 28.2 percent to $4.51 after gaining 9.32 percent on Wednesday. STAAR Surgical Company (NASDAQ: STAA) shares jumped 27.8 percent to $21.40 after reporting upbeat Q1 results. Boxlight Corporation (NASDAQ: BOXL) rose 20.5 percent to $8.920 after climbing 107.87 percent on Wednesday. Xspand Products Lab Inc (NASDAQ: XSPL) gained 19.5 percent to $ 5.97. Xspand Products priced its IPO at $5 per share. YRC Worldwide Inc. (NASDAQ: YRCW) rose 18.9 percent to $10.035 following upbeat quarterly earnings. ENDRA Life Sciences Inc. (NASDAQ: NDRA) gained 18.3 percent to $3.0177. ENDRA Life Sciences is expected to report Q1 results on May 15. MYR Group Inc. (NASDAQ: MYRG) rose 18.1 percent to $35.85 after the company posted strong Q1 earnings. Rudolph Technologies, Inc. (NASDAQ: RTEC) shares jumped 16 percent to $30.75 following upbeat quarterly earnings. TTM Technologies, Inc. (NASDAQ: TTMI) gained 13.7 percent to $16.53 after reporting Q1 results. Insight Enterprises, Inc. (NASDAQ: NSIT) shares surged 12 percent to $40.06 following better-than-expected Q1 earnings. TreeHouse Foods, Inc. (NYSE: THS) rose 11.8 percent to $40.93 following Q1 results. Engility Holdings, Inc. (NYSE: EGL) surged 11.2 percent to $27.36. Engility reported upbeat quarterly earnings. Synalloy Corporation (NASDAQ: SYNL) rose 10.7 percent to $19.10 following Q1 results. Logitech International S.A. (NASDAQ: LOGI)
  • [By Stephan Byrd]

    Marten Transport (NASDAQ: MRTN) and YRC Worldwide (NASDAQ:YRCW) are both small-cap transportation companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

  • [By Lisa Levin] Gainers Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 155.56 percent to close at $5.75 on Thursday. Inspire Medical Systems, Inc. (NYSE: INSP) shares gained 56.12 percent to close at $24.98. Inspire Medical went public Thursday on the New York Stock Exchange. The company issued 6.75 million shares priced at $16 each. Presbia PLC (NASDAQ: LENS) shares rose 53.02 percent to close at $3.55. Integrated Media Technology Limited (NASDAQ: IMTE) shares rose 46.29 percent to close at $32.11. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months. Technical Communications Corporation (NASDAQ: TCCO) climbed 27.78 percent to close at $5.75. STAAR Surgical Company (NASDAQ: STAA) shares gained 26.27 percent to close at $21.15 after reporting upbeat Q1 results. Sharing Economy International Inc. (NASDAQ: SEII) shares jumped 22.16 percent to close at $4.30 on Thursday after gaining 9.32 percent on Wednesday. China Advanced Construction Materials Group, Inc. (NASDAQ: CADC) rose 20.45 percent to close at $2.65 on Thursday. YRC Worldwide Inc. (NASDAQ: YRCW) surged 18.36 percent to close at $9.99 following upbeat quarterly earnings. MYR Group Inc. (NASDAQ: MYRG) jumped 17.68 percent to close at $35.74 after the company posted strong Q1 earnings. Xspand Products Lab Inc (NASDAQ: XSPL) jumped 17.4 percent to close at $5.87. Xspand Products priced its IPO at $5 per share. Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose 17.32 percent to close at $14.90. Coherus BioSciences reported resubmission of BLA for CHS-1701. Rudolph Technologies, Inc. (NASDAQ: RTEC) shares gained 17.17 percent to close at $31.05 following upbeat quarterly earnings. The Meet Group, Inc. (NASDAQ: MEET) gained 16.02 percent to close at $2.68 following Q1 earnings. Ca

Top 10 Penny Stocks To Watch For 2019: Sirius XM Radio Inc.(SIRI)

Advisors' Opinion:
  • [By Lisa Levin] Companies Reporting Before The Bell Thermo Fisher Scientific Inc. (NYSE: TMO) is projected to report quarterly earnings at $2.4 per share on revenue of $5.63 billion. Ford Motor Company (NYSE: F) is expected to report quarterly earnings at $0.41 per share on revenue of $37.16 billion. Twitter, Inc. (NYSE: TWTR) is projected to report quarterly earnings at $0.11 per share on revenue of $605.26 million. Comcast Corporation (NASDAQ: CMCSA) is expected to report quarterly earnings at $0.59 per share on revenue of $22.75 billion. General Dynamics Corporation (NYSE: GD) is estimated to report quarterly earnings at $2.52 per share on revenue of $7.6 billion. The Boeing Company (NYSE: BA) is expected to report quarterly earnings at $2.58 per share on revenue of $22.24 billion. Anthem, Inc. (NYSE: ANTM) is estimated to report quarterly earnings at $4.91 per share on revenue of $22.52 billion. Viacom, Inc. (NASDAQ: VIAB) is projected to report quarterly earnings at $0.79 per share on revenue of $3.04 billion. Northrop Grumman Corporation (NYSE: NOC) is estimated to report quarterly earnings at $3.61 per share on revenue of $6.61 billion. Rockwell Automation Inc. (NYSE: ROK) is expected to report quarterly earnings at $1.81 per share on revenue of $1.66 billion. Wipro Limited (NYSE: WIT) is projected to report quarterly earnings at $0.07 per share on revenue of $2.15 billion. The Goodyear Tire & Rubber Company (NASDAQ: GT) is expected to report quarterly earnings at $0.46 per share on revenue of $3.82 billion. Owens Corning (NYSE: OC) is projected to report quarterly earnings at $0.97 per share on revenue of $1.62 billion. T. Rowe Price Group, Inc. (NASDAQ: TROW) is estimated to report quarterly earnings at $1.71 per share on revenue of $1.29 billion. Dr Pepper Snapple Group, Inc. (NYSE: DPS) is expected to report quarterly earnings at $1.04 per share on revenue of $1.57 billion. Sirius XM Holdings Inc. (NASDAQ: SI
  • [By ]

    Remember, Apple (AAPL) had run because its service-revenue stream made the tech giant part of an elite group of companies. It joined Costco (COST) , Netflix (NFLX) , and SiriusXM (SIRI) , Spotify (SPOT) and Amazon (AMZN) (home of Amazon Prime) as companies that charge you recurring fees that you don't seem to notice or care about. So, Apple's stock no longer represents the tug to the group, and each company has to develop a separate power base away from Cupertino.

  • [By Rick Munarriz]

    There are two ways to buy into the country's lone provider of satellite radio, and one Wall Street pro thinks you should consider the road less traveled. Buckingham analyst Matthew Harrigan is downgrading shares of Sirius XM Holdings (NASDAQ:SIRI) on Monday, lowering his rating from buy to neutral.�

  • [By ]

    However, several Buffett stocks chalked up nice gains during the first quarter. The three top performers in Berkshire's portfolio were Sirius XM Holdings (NASDAQ:SIRI), Mastercard (NYSE:MA), and Moody's (NYSE:MCO). Here's what drove these stocks higher -- and what their prospects are for the rest of 2018.

Top 10 Penny Stocks To Watch For 2019: Nicholas Financial Inc.(NICK)

Advisors' Opinion:
  • [By Stephan Byrd]

    Nicholas Financial (NASDAQ: NICK) and CPI Card Group (NASDAQ:PMTS) are both small-cap finance companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

  • [By Ethan Ryder]

    Nicholas Financial (NASDAQ: NICK) and Encore Capital Group (NASDAQ:ECPG) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

  • [By Max Byerly]

    CPI Card Group (NASDAQ: PMTS) and Nicholas Financial (NASDAQ:NICK) are both small-cap business services companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Top 10 Penny Stocks To Watch For 2019: BioDelivery Sciences International Inc.(BDSI)

Advisors' Opinion:
  • [By Lisa Levin]

    BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares were also up, gaining 19 percent to $2.3272 after the company announced board restructuring plan and $50m equity financing deal led by Broadfin to "significantly strengthen" financial position.

Top 10 Penny Stocks To Watch For 2019: China Pharma Holdings Inc.(CPHI)

Advisors' Opinion:
  • [By Logan Wallace]

    These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

    Get Scynexis alerts: Steady Activities: SCYNEXIS, Inc. (NASDAQ:SCYX), LPL Financial Holdings Inc. (NASDAQ:LPLA) (oracleexaminer.com) Do Analysts Think You Should Buy �� SCYNEXIS Inc (NASDAQ: SCYX) (stockspen.com) Notable Runner: SCYNEXIS, Inc. (SCYX) (nasdaqplace.com) Most Active Stocks Now: SCYNEXIS, Inc. (NASDAQ:SCYX), China Pharma Holdings, Inc. (NYSE:CPHI), Kala … (journalfinance.net) Overview on price to free cash flow: SCYNEXIS, Inc. (NASDAQ:SCYX), InfuSystem Holdings Inc. (NYSE:INFU) (stocksnewspoint.com)

    Several research analysts have recently issued reports on the company. Roth Capital assumed coverage on Scynexis in a research note on Tuesday, May 8th. They set a “buy” rating and a $6.00 price target for the company. Seaport Global Securities assumed coverage on Scynexis in a research note on Tuesday, April 10th. They set a “buy” rating and a $4.00 price target for the company. Zacks Investment Research raised Scynexis from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Tuesday, May 8th. HC Wainwright assumed coverage on Scynexis in a research note on Monday, May 7th. They set a “buy” rating and a $5.00 price target for the company. Finally, ValuEngine raised Scynexis from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Scynexis currently has an average rating of “Buy” and an average target price of $4.45.

Top 10 Penny Stocks To Watch For 2019: Flanigan's Enterprises Inc.(BDL)

Advisors' Opinion:
  • [By Lisa Levin] Gainers Blink Charging Co. (NASDAQ: BLNK) shares jumped 26.5 percent to $6.9042. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million. Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares climbed 17.4 percent to $3.11. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share. Flanigan's Enterprises, Inc. (NYSE: BDL) shares jumped 17 percent to $27.97 following Q2 results. Flanigan's Enterprises posted Q2 earnings of $0.75 per share on sales of $29.456 million. Borqs Technologies, Inc. (NASDAQ: BRQS) rose 15.8 percent to $8.05 after reporting Q1 results. Abaxis, Inc. (NASDAQ: ABAX) jumped 15.3 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash. 21Vianet Group, Inc. (NASDAQ: VNET) gained 15.1 percent to $6.33. Gemphire Therapeutics Inc. (NASDAQ: GEMP) rose 13.8 percent to $6.27. Enphase Energy, Inc. (NASDAQ: ENPH) gained 12.8 percent to $5.98. H.C. Wainwright initiated coverage on Enphase Energy with a Buy rating. PetIQ Inc (NASDAQ: PETQ) shares surged 12.1 percent to $21.68 after reporting a first-quarter sales beat. NF Energy Saving Corporation (NASDAQ: NFEC) climbed 11.6 percent to $2.399. Allied Healthcare Products, Inc. (NASDAQ: AHPI) surged 11.4 percent to $3.0643. Boot Barn Holdings, Inc. (NYSE: BOOT) gained 11.1 percent to $24.40 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance. Ascena Retail Group, Inc. (NASDAQ: ASNA) rose 10.9 percent to $3.16. Sea Limited (NYSE: SE) gained 10.1 percent to $11.71 after reporting Q1 results. GEE Group, Inc. (NYSE: JOB) climbed 7.9 percent to $2.61 following Q2 results. The ONE Group Hospitality, Inc. (NASDAQ: STKS) gained 7.6 percent to $2.41 after reporting Q1 results. Biolinerx Ltd/S ADR (NASDAQ: BLRX) rose 7.3 percent to $0.8798 after the company was granted a patent approval. The clinical-st

Top 10 Penny Stocks To Watch For 2019: Rocky Mountain Chocolate Factory Inc.(RMCF)

Advisors' Opinion:
  • [By Ethan Ryder]

    Rocky Mountain Chocolate Factory (NASDAQ: RMCF) and Tootsie Roll Industries (NYSE:TR) are both small-cap retail/wholesale companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

  • [By Max Byerly]

    Rocky Mountain Chocolate Factory (NASDAQ: RMCF) and Tootsie Roll Industries (NYSE:TR) are both small-cap retail/wholesale companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Top 10 Penny Stocks To Watch For 2019: UFP Technologies Inc.(UFPT)

Advisors' Opinion:
  • [By Logan Wallace]

    China XD Plastics (NASDAQ: CXDC) and UFP Technologies (NASDAQ:UFPT) are both small-cap basic materials companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

  • [By Joseph Griffin]

    UFP Technologies (NASDAQ: UFPT) and China XD Plastics (NASDAQ:CXDC) are both small-cap industrial products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.